Show simple item record

dc.contributor.authorStrain, David
dc.date.accessioned2021-03-23T14:24:46Z
dc.date.available2021-03-23T14:24:46Z
dc.date.issued2021-01
dc.identifier.citationMaskery MP et al. Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. J Cereb Blood Flow Metab. 2021 Jan;41(1):14-30. doi: 10.1177/0271678X20952011. Epub 2020 Sep 20.en_US
dc.identifier.pmid32954901
dc.identifier.doi10.1177/0271678X20952011
dc.identifier.urihttps://rde.dspace-express.com/handle/11287/621682
dc.description.abstractStroke mortality and morbidity is expected to rise. Despite considerable recent advances within acute ischemic stroke treatment, scope remains for development of widely applicable neuroprotective agents. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally licensed for the management of Type 2 Diabetes Mellitus, have demonstrated pre-clinical neuroprotective efficacy in a range of neurodegenerative conditions. This systematic scoping review reports the pre-clinical basis of GLP-1RAs as neuroprotective agents in acute ischemic stroke and their translation into clinical trials. We included 35 pre-clinical studies, 11 retrospective database studies, 7 cardiovascular outcome trials and 4 prospective clinical studies. Pre-clinical neuroprotection was demonstrated in normoglycemic models when administration was delayed by up to 24 h following stroke induction. Outcomes included reduced infarct volume, apoptosis, oxidative stress and inflammation alongside increased neurogenesis, angiogenesis and cerebral blood flow. Improved neurological function and a trend towards increased survival were also reported. Cardiovascular outcomes trials reported a significant reduction in stroke incidence with semaglutide and dulaglutide. Retrospective database studies show a trend towards neuroprotection. Prospective interventional clinical trials are on-going, but initial indicators of safety and tolerability are favourable. Ultimately, we propose that repurposing GLP-1RAs is potentially advantageous but appropriately designed trials are needed to determine clinical efficacy and cost-effectiveness.en_US
dc.language.isoenen_US
dc.publisherAtyponen_US
dc.relation.urlhttps://journals.sagepub.com/doi/10.1177/0271678X20952011?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmeden_US
dc.rightsCopyright © 2021, © SAGE Publicationsen_US
dc.subjectAcute strokeen_US
dc.subjectanimal modelsen_US
dc.subjectclinical trialsen_US
dc.subjectneuroprotectionen_US
dc.subjectreperfusionen_US
dc.titleGlucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping reviewen_US
dc.typeJournal Articleen_US
dc.identifier.journalJournal of Cerebral Blood Flow & Metabolismen_US
dc.identifier.pmcidPMC7747170 (available on 2022-01-01)
dc.description.noteThis article is available to RD&E staff via NHS OpenAthens (subject to any publisher embargo). Click on the Publisher URL, and log in with NHS OpenAthens if prompted.en_US
dc.description.fundingThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CH is a named inventor on several patent applications that cover the use of GLP-1RAs for the treatment of neurodegenerative disorders. WDS has received speaker honoraria, conference sponsorship by Astra-Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Colgate Palmolive, Eli Lilly, GlaxoSmithKline, Lundbeck, Menarini, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Servier, and Takeda. He holds research grants from Astra-Zeneca, Novo Nordisk and Novartis.en_US
dc.type.versionPublisheden_US
dc.description.admin-notepublished version, accepted versionen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record